Defusing the
LDL-C Threat
Each day >2500 US adults die of CVD,1 despite available therapies
ASCVD remains a threat to public health2
It’s time to expect more
NewAmsterdam Pharma recognizes the need for alternative pharmacologic approaches to LDL-C management and is committed to developing novel, nonstatin, oral therapies that will potentially reduce patients' ASCVD risk.
Consider the link between ASCVD and LDL-C
Achieving LDL-C
goals matters
LLT considerations
Get the latest on emergent treatments
ASCVD, atherosclerotic cardiovascular disease; CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy.
References: 1. Tsao CW, Aday AW, Almarzooq ZI, et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93-e621. 2. Makover ME, Shapiro MD, Toth PP. There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: a review of current practice and recommendations for improved effectiveness. Am J Prev Cardiol. 2022;12:100371.